OPDUALAG

Google image searchProduct monograph

Active ingredients

nivolumab, 240 MG/20 ML

relatlimab, 80 MG/20 ML

DIN: 02541416

Dosage form(s): SOLUTION

Route(s) of administration: INTRAVENOUS

Description: SINGLE-USE VIAL

Schedule: Prescription / Schedule D

Company: BRISTOL-MYERS SQUIBB CANADA

Date: 12-FEB-2024

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
• L01FY — Combinations of monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
• L01FY02 — NIVOLUMAB AND RELATLIMAB (ATC/DDD)

External Links for Opdualag

Search on Google

• Opdualag side effects
• Opdualag dosage
• nivolumab side effects
• nivolumab dosage
• relatlimab side effects
• relatlimab dosage

Bristol-Myers Squibb Canada

Go to Bristol-Myers Squibb website to see drug product details. Sometimes you can find opdualag photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.